Jean-Yves Blay Selected Research

Leiomyosarcoma

11/2020	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
1/2020	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
11/2019	RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas.
1/2019	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.
10/2018	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.
1/2018	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.
1/2018	Gastrointestinal stromal tumors (GIST) presenting in the liver: Diagnostic, prognostic and therapeutic issues.
10/2017	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
4/2017	Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.
1/2017	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Yves Blay Research Topics

Disease

176	Neoplasms (Cancer) 06/2022 - 06/2002
145	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2003
54	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 06/2022 - 08/2004
30	Disease Progression 01/2022 - 01/2006
25	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2007
20	Neutropenia 01/2022 - 05/2006
20	Leiomyosarcoma 11/2020 - 08/2006
19	Breast Neoplasms (Breast Cancer) 01/2022 - 06/2004
18	Hypertension (High Blood Pressure) 01/2022 - 07/2009
17	Osteosarcoma (Osteogenic Sarcoma) 06/2022 - 07/2005
17	Fatigue 01/2022 - 09/2006
12	Liposarcoma 01/2022 - 01/2004
12	Nausea 01/2022 - 09/2006
11	Synovial Sarcoma (Synovioma) 07/2019 - 01/2004
10	Hemangiosarcoma (Angiosarcoma) 01/2022 - 11/2008
9	Thrombocytopenia (Thrombopenia) 01/2022 - 02/2008
9	Lymphopenia (Lymphocytopenia) 12/2021 - 12/2004
7	Brain Neoplasms (Brain Tumor) 01/2022 - 09/2005
7	Aggressive Fibromatosis (Desmoid) 01/2021 - 10/2008
7	Ewing Sarcoma (Sarcoma, Ewing) 01/2020 - 10/2008
7	Febrile Neutropenia 11/2016 - 12/2004
6	Giant Cell Tumors (Giant Cell Tumor) 03/2021 - 09/2012
6	Colorectal Neoplasms (Colorectal Cancer) 06/2020 - 07/2007
6	Melanoma (Melanoma, Malignant) 01/2020 - 08/2010
6	Lymphoma (Lymphomas) 01/2017 - 06/2004
5	Infections 01/2022 - 05/2006
5	COVID-19 01/2022 - 01/2021
4	Carcinoma (Carcinomatosis) 01/2022 - 06/2004
4	Hyperthermia 10/2021 - 06/2010
4	Giant Cell Tumor of Bone 01/2021 - 08/2012
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2020 - 12/2005
4	Weight Loss (Weight Reduction) 01/2020 - 05/2012
4	Myxoid Liposarcoma 03/2019 - 07/2007
4	Exanthema (Rash) 06/2014 - 09/2006
3	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2011
3	Chondrosarcoma 11/2021 - 01/2017
3	Anemia 11/2021 - 04/2003
3	Pain (Aches) 01/2021 - 01/2017
3	Chordoma 01/2021 - 11/2016

Drug/Important Bio-Agent (IBA)

65	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 06/2002
29	Tyrosine Kinase InhibitorsIBA 12/2021 - 03/2007
28	TrabectedinIBA 01/2022 - 11/2005
27	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 11/2005
19	Biomarkers (Surrogate Marker)IBA 06/2022 - 06/2004
19	Ifosfamide FDA LinkGeneric 12/2021 - 11/2005
18	Sunitinib (Sutent)FDA Link 01/2022 - 03/2007
15	Pharmaceutical PreparationsIBA 01/2022 - 06/2004
13	Biological ProductsIBA 01/2022 - 11/2005
13	Phosphotransferases (Kinase)IBA 12/2021 - 03/2007
13	regorafenibIBA 11/2021 - 01/2013
11	pazopanib FDA Link 12/2020 - 07/2009
10	Denosumab FDA Link 03/2021 - 08/2012
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 06/2004
9	CytokinesIBA 01/2022 - 12/2005
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2007
9	AnthracyclinesIBA 12/2021 - 07/2012
8	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2021 - 08/2004
8	VemurafenibIBA 01/2020 - 08/2015
8	Cytotoxins (Cytolysins)IBA 06/2017 - 06/2004
7	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2007
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 03/2006
7	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 03/2006
7	Alanine Transaminase (SGPT)IBA 01/2020 - 10/2008
7	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 10/2009
6	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2019
6	CrizotinibIBA 12/2021 - 01/2015
6	Sorafenib (BAY 43-9006)FDA Link 11/2021 - 01/2012
6	LigandsIBA 01/2021 - 05/2011
6	Docetaxel (Taxotere)FDA Link 01/2020 - 08/2006
6	Interleukin-10 (Interleukin 10)IBA 03/2013 - 06/2004
6	Interleukin-6 (Interleukin 6)IBA 08/2011 - 06/2004
5	nilotinib FDA Link 12/2021 - 09/2009
5	ripretinibIBA 12/2021 - 01/2020
5	AntibodiesIBA 12/2021 - 07/2007
5	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2019
5	Gemcitabine FDA Link 01/2020 - 08/2006
5	Messenger RNA (mRNA)IBA 01/2020 - 08/2011
5	Monoclonal AntibodiesIBA 12/2017 - 11/2009
5	MicroRNAs (MicroRNA)IBA 06/2015 - 01/2011
4	cabozantinibIBA 06/2022 - 01/2020
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 03/2015
4	Transaminases (Aminotransferases)IBA 01/2020 - 06/2009
4	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 11/2008
4	eribulin FDA Link 01/2019 - 10/2011
4	Bevacizumab (Avastin)FDA Link 10/2018 - 07/2007
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2010 - 08/2004
3	ParaffinIBA 01/2022 - 05/2011
3	VaccinesIBA 01/2022 - 01/2021
3	Anaplastic Lymphoma KinaseIBA 12/2021 - 01/2018

Therapy/Procedure

90	Therapeutics 06/2022 - 02/2005
73	Drug Therapy (Chemotherapy) 01/2022 - 01/2003
25	Radiotherapy 01/2022 - 07/2005
13	Adjuvant Chemotherapy 01/2022 - 03/2006
10	Immunotherapy 01/2022 - 03/2013
9	Neoadjuvant Therapy 01/2022 - 03/2006
8	Precision Medicine 01/2022 - 06/2013
4	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 10/2011
4	Intravenous Infusions 08/2016 - 01/2012
3	Drug Tapering 01/2022 - 05/2006
3	Duration of Therapy 11/2021 - 01/2009